Compare Bristol-Myers Squibb Co (BMY) vs Flagstar Bank NA (FLG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Flagstar Bank NA — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while Flagstar Bank NA trades at $14.95 (market cap $6.24B). The key difference: Bristol-Myers Squibb Co is far larger — about 18.6× Flagstar Bank NA's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | FLG | |
|---|---|---|
Market Cap | $116.30B | $6.24B |
Sector | Health | Financials |
52-Week High | $62.37 | $15.28 |
52-Week Low | $42.60 | $10.72 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | 0.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Flagstar Bank (FLG) trades at $14.88, down 1.39% today, with a bullish technical outlook supported by moving averages. The stock shows improving fundamentals with two consecutive quarterly EPS beats and a positive Q1 2026 net income of $0.04 per share. Recent news highlights management's focus on technology transformation and balance sheet stabilization, while the P/B ratio of 0.82 indicates potential undervaluation relative to book value.
The outlook is cautiously optimistic with a consensus price target of $17.05 offering 14.6% upside. Risks include negative net income margins and high interest expenses, but analyst sentiment is positive with no sell ratings. The upcoming Q2 2026 earnings report on July 24, 2026, will be critical for confirming the turnaround trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →
